Literature DB >> 15336778

HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis.

Vincent R Bonagura1, Andrea Vambutas, James A DeVoti, David W Rosenthal, Bettie M Steinberg, Allan L Abramson, Mark J Shikowitz, David W Gjertson, Elaine F Reed.   

Abstract

Recurrent respiratory papillomatosis (RRP) remains an immunologic enigma. Human papillomavirus (HPV) types 6 and 11 are the predominant HPV viruses that cause papilloma development. However, it is unclear why only a very small fraction of HPV-exposed individuals develop RRP. We performed high-resolution HLA class I and II genotyping on 70 randomly selected patients (56 Caucasians and 14 African-Americans) with RRP. We report, for the first time, an increased frequency of HLA-DRB1*0102 in Caucasian patients with RRP, suggesting that this allele predisposes individuals to RRP. Additionally, HLA-DRB1*0301, DQB1*0201, and DQB1*0202 alleles were selectively enriched in Caucasians with severe disease, suggesting that these alleles may regulate disease severity. In contrast, HLA-DQB1*0602 was more frequent in controls than in Caucasians with severe disease, suggesting a severity-sparing effect of this allele. Furthermore, both DQB1*0201 and DQB1*0202 were enriched, whereas DQB1*0602 was absent, in African-Americans. Interestingly, HLA-DRB1*0301 and DQB1*0201 correlated with reduced interferon-gamma expression in patients with RRP. Larger studies are needed to identify other class II major histocompatibility complex alleles that may influence disease predisposition, disease severity, or both, especially in African-American patients, to ultimately illuminate the regulatory effects of these alleles in the predisposition and severity of RRP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15336778     DOI: 10.1016/j.humimm.2004.05.014

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  20 in total

1.  Pneumomediastinum and retroperitoneal air after removal of papillomas with the microdebrider and jet ventilation.

Authors:  H Steven Sims; Keith Lertsburapa
Journal:  J Natl Med Assoc       Date:  2007-09       Impact factor: 1.798

2.  Decreased Langerhans cell responses to IL-36γ: altered innate immunity in patients with recurrent respiratory papillomatosis.

Authors:  James DeVoti; Lynda Hatam; Alexandra Lucs; Ali Afzal; Allan Abramson; Bettie Steinberg; Vincent Bonagura
Journal:  Mol Med       Date:  2014-08-28       Impact factor: 6.354

3.  Characterization of human papillomavirus type 11-specific immune responses in a preclinical model.

Authors:  Shiwen Peng; Simon R Best; Chien-Fu Hung; Myriam Loyo; Sofia Lyford-Pike; Paul W Flint; David E Tunkel; John R Saunders; T C Wu; Sara I Pai
Journal:  Laryngoscope       Date:  2010-03       Impact factor: 3.325

4.  Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.

Authors:  Eddie A James; James A DeVoti; David W Rosenthal; Lynda J Hatam; Bettie M Steinberg; Allan L Abramson; William W Kwok; Vincent R Bonagura
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

Review 5.  Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Authors:  Vincent R Bonagura; Lynda J Hatam; David W Rosenthal; James A de Voti; Fung Lam; Bettie M Steinberg; Allan L Abramson
Journal:  APMIS       Date:  2010-06       Impact factor: 3.205

6.  Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression.

Authors:  Corina Heller; Tanja Weisser; Antje Mueller-Schickert; Elke Rufer; Alexander Hoh; Ralf M Leonhardt; Michael R Knittler
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

7.  Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis.

Authors:  Vincent R Bonagura; Zeying Du; Elham Ashouri; Lihui Luo; Lynda J Hatam; James A DeVoti; David W Rosenthal; Bettie M Steinberg; Allan L Abramson; David W Gjertson; Elaine F Reed; Raja Rajalingam
Journal:  Hum Immunol       Date:  2009-10-25       Impact factor: 2.850

8.  Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis.

Authors:  James A DeVoti; David W Rosenthal; Rong Wu; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

Review 9.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 10.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.